Teva Pharmaceutical Industries Ltd (TEVA) Expected to Post Earnings of $0.74 Per Share

Wall Street brokerages forecast that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will announce earnings per share (EPS) of $0.74 for the current quarter, Zacks reports. Two analysts have made estimates for Teva Pharmaceutical Industries’ earnings. The lowest EPS estimate is $0.69 and the highest is $0.84. Teva Pharmaceutical Industries reported earnings of $1.06 per share during the same quarter last year, which would indicate a negative year over year growth rate of 30.2%. The firm is expected to announce its next earnings results on Thursday, May 10th.

According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full-year earnings of $2.91 per share for the current year, with EPS estimates ranging from $2.39 to $3.40. For the next fiscal year, analysts anticipate that the company will post earnings of $3.31 per share, with EPS estimates ranging from $2.85 to $3.67. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 14.52% and a negative net margin of 72.66%. The business had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the firm earned $1.38 EPS. Teva Pharmaceutical Industries’s revenue was down 15.9% on a year-over-year basis.

A number of equities analysts have weighed in on the company. Leerink Swann decreased their target price on Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating for the company in a research report on Friday. BTIG Research lowered Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating and set a $17.00 target price for the company. in a research report on Friday, February 2nd. Oppenheimer reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday. Piper Jaffray Companies lowered Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and set a $11.00 target price for the company. in a research report on Friday. Finally, Cantor Fitzgerald set a $18.00 price target on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Wednesday, January 3rd. Ten equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $21.26.

Several large investors have recently made changes to their positions in the stock. Schroder Investment Management Group boosted its stake in Teva Pharmaceutical Industries by 22.7% in the 3rd quarter. Schroder Investment Management Group now owns 6,194,083 shares of the company’s stock worth $106,290,000 after purchasing an additional 1,147,683 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its stake in Teva Pharmaceutical Industries by 4.5% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,035,644 shares of the company’s stock worth $106,271,000 after purchasing an additional 259,891 shares during the period. State Street Corp boosted its stake in Teva Pharmaceutical Industries by 5.1% in the 2nd quarter. State Street Corp now owns 4,763,692 shares of the company’s stock worth $158,254,000 after purchasing an additional 232,924 shares during the period. Macquarie Group Ltd. boosted its stake in Teva Pharmaceutical Industries by 350.3% in the 3rd quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock worth $77,587,000 after purchasing an additional 3,429,448 shares during the period. Finally, Swiss National Bank boosted its stake in Teva Pharmaceutical Industries by 0.9% in the 4th quarter. Swiss National Bank now owns 3,523,499 shares of the company’s stock worth $66,770,000 after purchasing an additional 32,000 shares during the period. Institutional investors own 51.93% of the company’s stock.

Teva Pharmaceutical Industries (NYSE:TEVA) opened at $18.91 on Monday. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $37.94. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. The firm has a market capitalization of $18,907.76, a PE ratio of -1.14, a price-to-earnings-growth ratio of 1.37 and a beta of 0.60.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Ltd (TEVA) Expected to Post Earnings of $0.74 Per Share” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/12/teva-pharmaceutical-industries-ltd-teva-expected-to-post-earnings-of-0-74-per-share.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply